[Federal Register Volume 72, Number 76 (Friday, April 20, 2007)]
[Rules and Regulations]
[Page 19796]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E7-7472]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Part 520


Oral Dosage Form New Animal Drugs; Clindamycin Solution

AGENCY:  Food and Drug Administration, HHS.

ACTION:  Final rule.

-----------------------------------------------------------------------

SUMMARY:  The Food and Drug Administration (FDA) is amending the animal 
drug regulations to reflect approval of an abbreviated new animal drug 
application (ANADA) filed by First Priority, Inc. The ANADA provides 
for the veterinary prescription use of clindamycin hydrochloride oral 
solution in dogs and cats for the treatment of various infections due 
to susceptible bacterial pathogens.

DATES:  This rule is effective April 20, 2007.

FOR FURTHER INFORMATION CONTACT:  John K. Harshman, Center for 
Veterinary Medicine (HFV-104), Food and Drug Administration, 7500 
Standish Pl., Rockville, MD 20855, 301-827-0169, e-mail: 
<a href="/cdn-cgi/l/email-protection#59333631377731382b2a31343837193f3d387731312a773e362f"><span class="__cf_email__" data-cfemail="1b7174737535737a696873767a755b7d7f7a35737368357c746d">[email protected]</span></a>.

SUPPLEMENTARY INFORMATION: First Priority, Inc., 1585 Todd Farm Dr., 
Elgin, IL 60123, filed ANADA 200-398 for the veterinary prescription 
use of Clindamycin Hydrochloride Oral Drops in dogs and cats for the 
treatment of various infections due to susceptible bacterial pathogens. 
First Priority, Inc.'s Clindamycin Hydrochloride Oral Drops is approved 
as a generic copy of ANTIROBE AQUADROPS Liquid, sponsored by Pharmacia 
& Upjohn Co., a Division of Pfizer, Inc., under NADA 135-940. The ANADA 
is approved as of March 19, 2007, and 21 CFR 520.447 is amended to 
reflect the approval.
    In accordance with the freedom of information provisions of 21 CFR 
part 20 and 21 CFR 514.11(e)(2)(ii), a summary of safety and 
effectiveness data and information submitted to support approval of 
this application may be seen in the Division of Dockets Management 
(HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, 
Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday.
    FDA has determined under 21 CFR 25.33(a)(1) that this action is of 
a type that does not individually or cumulatively have a significant 
effect on the human environment. Therefore, neither an environmental 
assessment nor an environmental impact statement is required.
    This rule does not meet the definition of ``rule'' in 5 U.S.C. 
804(3)(A) because it is a rule of ``particular applicability.'' 
Therefore, it is not subject to the congressional review requirements 
in 5 U.S.C. 801-808.

List of Subjects in 21 CFR Part 520

    Animal drugs.

0
Therefore, under the Federal Food, Drug, and Cosmetic Act and under 
authority delegated to the Commissioner of Food and Drugs and 
redelegated to the Center for Veterinary Medicine, 21 CFR part 520 is 
amended as follows:

PART 520--ORAL DOSAGE FORM NEW ANIMAL DRUGS

0
1. The authority citation for 21 CFR part 520 continues to read as 
follows:

    Authority:  21 U.S.C. 360b.

0
2. In Sec.  520.447 revise paragraph (b) to read as follows:


Sec.  520.447   Clindamycin Solution.

* * * * *
    (b) Sponsors. See Nos. 000009, 051311, 058829, and 059130 in Sec.  
510.600(c) of this chapter.
* * * * *

    Dated: April 9, 2007.
Bernadette Dunham,
Deputy Director, Center for Veterinary Medicine.
[FR Doc. E7-7472 Filed 4-19-07; 8:45 am]
BILLING CODE 4160-01-S


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>